Biohaven Just Went Through Hell — But Its CEO and Directors Still See an Angel

(Speculative biotech, spicy story, handle with care.) 👼

Biohaven is one of those biotechs that lives right at the intersection of brilliant science, brutal volatility, and bold conviction. 🧬🔥

On paper, it’s a familiar setup:

• No revenue yet

• Heavy R&D spend

• Regulatory heartbreak

• Massive potential markets

But Biohaven also has something not every biotech has:

• A battle-tested CEO who already built and sold the “first” Biohaven to Pfizer for ~$13 billion

• A wall of insider buying (including that same CEO)

• Institutions that keep showing up with real money

So… did Biohaven just walk through biotech hell to get closer to heaven — or is this just a fiery pit with better branding? Let’s dig in. 😏

🧬 What Does Biohaven Actually Do?

Biohaven is a clinical-stage biopharma shop focused on life-changing treatments in:

• Immunology (e.g., autoimmune diseases like IgA nephropathy, Graves’ disease)

• Neuroscience (epilepsy, depression, OCD, rare neuro disorders)

• Oncology & neuromuscular disease (SMA, obesity-related pathways, etc.)

Its pipeline includes:

• Kv7 ion channel modulators for epilepsy and mood disorders

• MoDE™ and TRAP™ extracellular protein degraders for immune diseases

• Myostatin pathway inhibition for SMA and obesity

In other words: this isn’t “one-drug-or-bust” biotech. It’s a multi-program, high-science platform story. 🧪

👨⚕️ The CEO: From $6 Million to $13 Billion (Round 1)

Before this version of Biohaven, Dr. Vlad Coric already played one biotech game on “hard mode” — and won:

• Took the original Biohaven from ~$6M pre-money to a $13B sale to Pfizer

• Brought Nurtec ODT from idea to FDA approval for both acute and preventive migraine treatment

• Helped file and advance zavegepant, an intranasal CGRP antagonist

• Has contributed to multiple major drugs at Yale & Bristol-Myers Squibb (Abilify, Opdivo, Yervoy, etc.)

Now he’s back, steering Biohaven 2.0 through a fresh round of pipeline building, setbacks, pivots, and… major personal share purchases.

If you like founder/CEO “skin in the game,” you’ll probably raise an eyebrow here. 🧐

💰 Insider Buys: “We Went Through Fire, We’re Still Buying”

The insider buys aren’t cute little 2,000-share gestures. They’re multi-million-dollar swings.

Recent highlight reel:

• John W. Childs (Director)

  • Bought 3,333,333 shares at $7.50 for ~$25M in November 2025

  • Has previously bought at $41, $47.50, $35–36, $30+ — many positions now deeply underwater

• Dr. Vlad Coric (CEO)

  • Bought 666,666 shares at $7.50 (~$5M) in November 2025

  • Previously purchased at $41 and $47.50

• Gregory Bailey (Director)

  • Added 400,000 shares at $7.50 (~$3M)

  • Has multiple prior buys in the $34–44 range

Taken together, this looks less like a casual “show of confidence” and more like a group of insiders saying:

“Yes, it’s ugly. Yes, it hurts. And yes, we’re still in.”

Is that a guarantee? Absolutely not.
Is it serious conviction? Absolutely yes. 💸🔥

🧨 What Went Wrong: FDA, Real-World Evidence & A 40% Cliff Dive

The recent faceplant moment came from Biohaven’s candidate Vyglxia (troriluzole) for spinocerebellar ataxia (SCA) — a brutal rare disease with no approved treatment.

• Biohaven submitted an NDA built heavily on real-world evidence (RWE) and external controls

• The FDA responded with a Complete Response Letter (CRL) in November 2025

• Concerns: bias, trial design, external control limitations, confounding

• The stock reacted like… biotech: down ~40–44% in a day

What stings is that:

• The RWE study (Study 206-RWE) reportedly showed 50–70% slowing of disease progression

• Multiple endpoints hit statistical significance

• Leading SCA experts publicly backed the data

• An Advisory Committee meeting was planned… then cancelled

Biohaven’s tone is basically:

“We brought strong data, the FDA brought a rigid playbook.”

They’re not giving up on Vyglxia — but the path is delayed, murky, and costly.

🔁 The Pivot: Dilution, Refocus, and Survival Mode (With a Plan)

After the CRL, Biohaven essentially hit the pipeline reset button:

1️⃣ Dilutive Equity Raise

• Upsized offering of ~23.3M shares at $7.50

• Underwriters exercised their option

• Gross proceeds ≈ $200M

• Painful for existing holders, but it extends the runway

2️⃣ Cost Cuts & Portfolio Focus

Biohaven is:

• Implementing ~60% reduction in direct R&D spend (excl. personnel/SBC)

• Prioritizing three key late-stage programs:

  1. Extracellular degraders (BHV-1400 for IgA nephropathy; BHV-1300 for Graves’ disease)

  2. Opakalim (Kv7 activator) for focal epilepsy and depression

  3. Taldefgrobep alfa for SMA and obesity

Everything else? Pushed out, slowed, or paused.

3️⃣ Additional Strategic Funding

• Deal with Oberland Capital for up to $600M in non-dilutive financing potential, tied to future troriluzole sales and milestones

• First $250M tranche already committed (pre-CRL), with additional capital contingent on regulatory progress

So yes, there’s real dilution, but also a serious attempt to shore up the balance sheet and focus on the highest-potential shots on goal. 🎯

🧠 Who Else Believes? Institutions & Analysts

Ownership snapshot:

• Insiders: ~9% of shares

• Institutions: ~66% of shares, ~72% of float

• 350+ institutional holders

Top holders include:

• BlackRock, Janus Henderson, Stifel, Suvretta, State Street, Vanguard, Bellevue, FMR (Fidelity)

For Biohaven (BHVN)'s Institutional Ownership breakdown, 🔍 see here.

Analyst vibes:

• Citigroup: Maintains Buy, trims target from $28 → $14

• RBC: Cuts target from $19 → $9, keeps Sector Perform, speculative risk

• Average target: still around mid-20s (with big dispersion)

Translation:
The Street still thinks there’s upside, but now it clearly wears a “speculative” label in bold neon.

📉 Current Snapshot: No Revenue, Narrowing Loss, Big Optionality

• Q3 2025 non-GAAP loss: -$1.47/share, improved from -$1.74

• Revenue: $0 (pure clinical-stage biotech mode)

• Cash & securities (pre-offering): ~$263.8M

• Plus: equity raise (~$200M gross) and the structured Oberland facility

 👉 Want the full picture? Dive into Biohaven (BHVN)'s financials here.

Also:

• Shares now trade far below the ~$62 all-time high (March 2024) [NYSE: BHVN $8.27: Closed: Nov 18, 4:23 AM EST]

• If things go right, the percentage upside can be huge

• If they don’t… well, biotech can always find a lower floor 😅

💡💡💡 Curious about another deep oil exploration play?
Check our takes on UnitedHealth Group or even Oscar Health.

⚡ Quick Take / TL;DR

• Biohaven = high-science, no-revenue biotech with multiple late-stage programs and a bruised-but-intact pipeline.

• FDA rejected its SCA drug Vyglxia, triggering a 40%+ stock crash and forcing a pivot in strategy and spending.

• The company responded with a $200M equity raise, 60% R&D cuts, and focus on 3 key programs (IgA nephropathy / Graves’ disease, epilepsy & depression, SMA & obesity).

• Insiders keep buying big (tens of millions of dollars at higher and lower prices), and institutions own ~2/3 of the stock.

• Analysts still see upside, but now explicitly label it speculative, high-risk, high-volatility.

• This is a “swing for the fences” biotech — potentially powerful upside if key trials work and approvals come, but very real risk of capital loss if they don’t.

❓ FAQ

Q: Is Biohaven profitable or generating product revenue?
A: No. Biohaven is pure clinical-stage right now — no approved products, no recurring revenue, and ongoing losses driven by R&D. This is 100% a pipeline and data story, not a current-earnings story.

Q: Why did the stock crash so hard in November 2025?
A: The FDA issued a Complete Response Letter declining to approve Vyglxia for SCA, despite Biohaven’s RWE data and strong support from disease experts. That single event vaporized a major near-term value pillar and triggered a brutal repricing.

Q: If the FDA said no, why are insiders still buying?
A: Insiders may believe:

• The pipeline beyond Vyglxia (IgA nephropathy, Graves’, epilepsy, depression, SMA, obesity) still justifies the risk

• Regulators might eventually find a path forward for SCA

• The current valuation over-discounts the setbacks

But remember: insiders can be wrong, too. Their conviction is a signal, not a guarantee.

Q: Is Biohaven a “value play” now?
A: Not in the classic sense. There are no earnings or cash flows to anchor traditional value metrics. It’s more of a “distressed growth biotech” with optionality: if even a couple of late-stage assets hit, today’s price could look cheap. If not… it’s just cheap for a reason.

Q: Who should even consider this stock?
A: Only investors who:

• Understand clinical and regulatory risk

• Accept extreme volatility and potential permanent losses

• Size positions small and diversified

• See speculative biotech as a slice, not the core, of their portfolio

🧾⚠️📢 Fun(anc1al) but Serious Disclaimer: 🧾⚠️📢

This is education + entertainment, not personalized financial advice. 🧾
Biohaven is a high-risk, high-volatility biotech with no current revenue, live regulatory scars, and a future that depends on clinical trial outcomes and FDA decisions — none of which are guaranteed.

Always DYOR, talk to a qualified advisor if needed, size positions to your risk tolerance, and never invest money you can’t afford to lose.

Between Biohaven and the FDA there hasn’t been much chemistry lately… so if you do invest, remember: in biotech, even angels tend to show up after the fire drill. 😇🔥

We’re not financial advisors. We’re FUNancial advisors. 🎪💸 

Invest at your own risk. 💸💧 

🧭 Want More Like This?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside
• 🧟 Corporate Resurrection Series — Our special series on companies rising from the financial grave. 🎯 The “Turnaround or Toast” Series (If it still exists. We’re not sure. Ask the intern.)
• 📈 Biotech Bets & Innovation Radar (Problem is we can't detect the Radar)

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny